<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Dent Res Dent Clin Dent Prospects</journal-id><journal-id journal-id-type="iso-abbrev">J Dent Res Dent Clin Dent Prospects</journal-id><journal-id journal-id-type="publisher-id">Journal of Dental Research, Dental Clinics, Dental Prospects</journal-id><journal-title-group><journal-title>Journal of Dental Research, Dental Clinics, Dental Prospects</journal-title></journal-title-group><issn pub-type="ppub">2008-210X</issn><issn pub-type="epub">2008-2118</issn><publisher><publisher-name>Tabriz University of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23875086</article-id><article-id pub-id-type="pmc">3713866</article-id><article-id pub-id-type="doi">10.5681/joddd.2013.015</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Efficacy of Pilocarpine and Bromhexine in Improving Radiotherapy-induced Xerostomia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Abbasi</surname><given-names>Farid</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Farhadi</surname><given-names>Sareh</given-names></name><xref ref-type="aff" rid="A02">
<sup>2</sup>
</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Esmaili</surname><given-names>Mostafa</given-names></name><xref ref-type="aff" rid="A03">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="A01"><sup>1</sup>Associate Professor, Department of Oral Medicine, Faculty of Dentistry, Shahed University, Tehran, Iran</aff><aff id="A02"><sup>2</sup>Assistant Professor, Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Shahed University, Tehran, Iran</aff><aff id="A03"><sup>3</sup>Assistant Professor, Department of Oral Medicine, Faculty of Dentistry, Shahed University, Tehran, Iran</aff><author-notes><corresp id="COR1"><label>*</label>Corresponding Author; <email>dr.sfarhadi@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Spring</season><year>2013</year></pub-date><pub-date pub-type="epub"><day>30</day><month>5</month><year>2013</year></pub-date><volume>7</volume><issue>2</issue><fpage>86</fpage><lpage>90</lpage><history><date date-type="received"><day>17</day><month>1</month><year>2012</year></date><date date-type="accepted"><day>6</day><month>3</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 The Authors; Tabriz University of Medical Sciences</copyright-statement><copyright-year>2013</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/3.0/" license-type="open-access"><license-p><ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:type="simple" xlink:href="http://dentistry.tbzmed.ac.ir/joddd">This article is available from: http://dentistry.tbzmed.ac.ir/joddd</self-uri><abstract><p><offsets xml_i="3464" xml_f="3465" txt_i="11" txt_f="12">
</offsets><bold><italic><offsets xml_i="3479" xml_f="3499" txt_i="12" txt_f="32">Background and aims.</offsets></italic></bold><offsets xml_i="3515" xml_f="3765" txt_i="32" txt_f="282"> Xerostomia is one of the most common complications of head and neck radiotherapy. The aim of this study was to evaluate and compare the efficacy of pilocarpine and bromhexine in improving radiotherapy-induced xerostomia and its associated symptoms.
</offsets></p><p><offsets xml_i="3772" xml_f="3773" txt_i="283" txt_f="284">
</offsets><bold><italic><offsets xml_i="3787" xml_f="3809" txt_i="284" txt_f="306">Materials and methods.</offsets></italic></bold><offsets xml_i="3825" xml_f="4685" txt_i="306" txt_f="1163"> In this single-blind, randomized crossover study, pilocarpine and bromhexine tablets were used by twenty-five patients suffered from xerostomia, with a medical history of head and neck radiotherapy. At step A, the patients were treated with pilocarpine for 2 weeks. In addition, they were asked to take bromhexine for 2 weeks with a one-week washout period. At step B, the inverse process was conducted (first bromhexine, then pilocarpine). Whole resting saliva was collected from patients before and after receiving each medication by precise measurements. Then, efficacy of the two drugs in the treatment of xerostomia and its related oral complications was evaluated using questionnaires by Dichotomous format. The results were statistically analyzed using t-student and Fisher’s exact and chi-squared tests. Statistical significance was set at P&lt;0.05.
</offsets></p><p><offsets xml_i="4692" xml_f="4693" txt_i="1164" txt_f="1165">
</offsets><bold><italic><offsets xml_i="4707" xml_f="4715" txt_i="1165" txt_f="1173">Results.</offsets></italic></bold><offsets xml_i="4731" xml_f="5075" txt_i="1173" txt_f="1517"> The difference between saliva secretion rates before and after medications was not significant for bromhexine users at two steps of the study (P=0.35); however, it was significant for pilocarpine users (P=0.0001). Users of both drugs showed significant differences in improvement of xerostomia, chewing, swallowing, tasting and mouth burning.
</offsets></p><p><offsets xml_i="5082" xml_f="5083" txt_i="1518" txt_f="1519">
</offsets><bold><italic><offsets xml_i="5097" xml_f="5108" txt_i="1519" txt_f="1530">Conclusion.</offsets></italic></bold><offsets xml_i="5124" xml_f="5365" txt_i="1530" txt_f="1771"> Pilocarpine is probably more effective in improving xerostomia and its associated problems compared with bromhexine, although the use of the latter was also shown to ease some of the consequences of radiotherapy in the head and neck region.</offsets></p></abstract><kwd-group><kwd>Bromhexine</kwd><kwd>pilocarpine</kwd><kwd>radiotherapy</kwd><kwd>xerostomia</kwd></kwd-group></article-meta></front><body><sec id="s1"><title><offsets xml_i="5539" xml_f="5551" txt_i="1779" txt_f="1791">Introduction</offsets></title><p><offsets xml_i="5562" xml_f="5698" txt_i="1792" txt_f="1928">
The importance of saliva in protecting the oral cavity becomes more apparent when malfunction of salivary glands results in xerostomia.</offsets><sup><xref rid="R01" ref-type="bibr"><offsets xml_i="5735" xml_f="5736" txt_i="1928" txt_f="1929">1</offsets></xref></sup><offsets xml_i="5749" xml_f="5982" txt_i="1929" txt_f="2162"> The problems experienced by patients may include a persistent dry or burning sensation, eating difficulties, diminution in taste acuity, discomfort during speaking, mucosal infections, denture intolerance and bacterial sialadenitis.</offsets><sup><xref rid="R02" ref-type="bibr"><offsets xml_i="6019" xml_f="6020" txt_i="2162" txt_f="2163">2</offsets></xref></sup><offsets xml_i="6033" xml_f="6174" txt_i="2163" txt_f="2304"> These symptoms reflect not only the mechanical function (moisture, irrigation and lubrication) of saliva, but also its buffering properties.</offsets><sup><xref rid="R03" ref-type="bibr"><offsets xml_i="6211" xml_f="6212" txt_i="2304" txt_f="2305">3</offsets></xref></sup><offsets xml_i="6225" xml_f="6226" txt_i="2305" txt_f="2306">
</offsets></p><p><offsets xml_i="6233" xml_f="6427" txt_i="2307" txt_f="2501">
Nowadays, consumption of antidepressant drugs, radiotherapy of the head and neck region and some systemic diseases, such as diabetes mellitus, are some of the conditions that induce xerostomia.</offsets><sup><xref rid="R04" ref-type="bibr"><offsets xml_i="6464" xml_f="6465" txt_i="2501" txt_f="2502">4</offsets></xref><offsets xml_i="6472" xml_f="6473" txt_i="2502" txt_f="2503">,</offsets><xref rid="R05" ref-type="bibr"><offsets xml_i="6505" xml_f="6506" txt_i="2503" txt_f="2504">5</offsets></xref></sup><offsets xml_i="6519" xml_f="6854" txt_i="2504" txt_f="2839"> Radiotherapy is used for suppression of malignant cells but injury to normal cells can be inevitable. Most of the patients with a history of head and neck radiotherapy complain of some degrees of xerostomia due to presence of salivary glands in the radiation field. Hence, destruction of gnathic bone and oral mucosa might be notable.</offsets><sup><xref rid="R06" ref-type="bibr"><offsets xml_i="6891" xml_f="6892" txt_i="2839" txt_f="2840">6</offsets></xref><offsets xml_i="6899" xml_f="6900" txt_i="2840" txt_f="2841">-</offsets><xref rid="R08" ref-type="bibr"><offsets xml_i="6932" xml_f="6933" txt_i="2841" txt_f="2842">8</offsets></xref></sup><offsets xml_i="6946" xml_f="7116" txt_i="2842" txt_f="3012"> A reduction in salivary flow rate and decrease of its pH is paralleled with a change in saliva competence and shifting of oral microflora to cariogenic bacterial spices.</offsets><sup><xref rid="R09" ref-type="bibr"><offsets xml_i="7153" xml_f="7154" txt_i="3012" txt_f="3013">9</offsets></xref></sup><offsets xml_i="7167" xml_f="7336" txt_i="3013" txt_f="3182"> Therefore, discomfort in chewing, swallowing, speech, sleep and also progressing of periodontal diseases and dental caries probably occur in the presence of xerostomia.</offsets><sup><xref rid="R10" ref-type="bibr"><offsets xml_i="7373" xml_f="7375" txt_i="3182" txt_f="3184">10</offsets></xref><offsets xml_i="7382" xml_f="7383" txt_i="3184" txt_f="3185">-</offsets><xref rid="R12" ref-type="bibr"><offsets xml_i="7415" xml_f="7417" txt_i="3185" txt_f="3187">12</offsets></xref></sup><offsets xml_i="7430" xml_f="7431" txt_i="3187" txt_f="3188">
</offsets></p><p><offsets xml_i="7438" xml_f="7574" txt_i="3189" txt_f="3325">
Studies have led to four therapeutic suggestions for xerostomia: preventive and symptomatic treatments, local and systemic stimulation.</offsets><sup><xref rid="R13" ref-type="bibr"><offsets xml_i="7611" xml_f="7613" txt_i="3325" txt_f="3327">13</offsets></xref><offsets xml_i="7620" xml_f="7621" txt_i="3327" txt_f="3328">-</offsets><xref rid="R15" ref-type="bibr"><offsets xml_i="7653" xml_f="7655" txt_i="3328" txt_f="3330">15</offsets></xref></sup><offsets xml_i="7668" xml_f="8055" txt_i="3330" txt_f="3717"> In relation to systemic medications, bromhexine is recognized as a diluting agent of mucous secretions in respiratory tract and pilocarpine is a parasympathomimetic medication acting as salivary and lacrimal secretion stimulator. Many studies have verified that pilocarpine can provide clinically significant symptomatic relief to patients suffering from radiotherapy-induced xerostomia</offsets><sup><xref rid="R10" ref-type="bibr"><offsets xml_i="8092" xml_f="8094" txt_i="3717" txt_f="3719">10</offsets></xref><offsets xml_i="8101" xml_f="8102" txt_i="3719" txt_f="3720">-</offsets><xref rid="R12" ref-type="bibr"><offsets xml_i="8134" xml_f="8136" txt_i="3720" txt_f="3722">12</offsets></xref></sup><offsets xml_i="8149" xml_f="8188" txt_i="3722" txt_f="3761"> and also in cases of Sjögren syndrome;</offsets><sup><xref rid="R16" ref-type="bibr"><offsets xml_i="8225" xml_f="8227" txt_i="3761" txt_f="3763">16</offsets></xref></sup><offsets xml_i="8240" xml_f="8311" txt_i="3763" txt_f="3834"> but there are few studies about efficacy of bromhexine in these cases.</offsets><sup><xref rid="R13" ref-type="bibr"><offsets xml_i="8348" xml_f="8350" txt_i="3834" txt_f="3836">13</offsets></xref><offsets xml_i="8357" xml_f="8358" txt_i="3836" txt_f="3837">-</offsets><xref rid="R15" ref-type="bibr"><offsets xml_i="8390" xml_f="8392" txt_i="3837" txt_f="3839">15</offsets></xref></sup><offsets xml_i="8405" xml_f="8536" txt_i="3839" txt_f="3970"> Furthermore, we could not find any reports making comparisons between efficacy of pilocarpine and bromhexine in these conditions.
</offsets></p><p><offsets xml_i="8543" xml_f="8720" txt_i="3971" txt_f="4148">
Therefore, this study was designed to evaluate and compare the efficacy of pilocarpine and bromhexine in improving radiotherapy-induced xerostomia and its associated symptoms.
</offsets></p></sec><sec sec-type="materials|methods" id="s2"><title><offsets xml_i="8779" xml_f="8800" txt_i="4150" txt_f="4171">Materials and Methods</offsets></title><p><offsets xml_i="8811" xml_f="9070" txt_i="4172" txt_f="4431">
This single-blind, randomized crossover study evaluated twenty-five patients of Imam Reza Hospital of Kermanshah, Iran, who suffered from xerostomia and their medical history showed head and neck radiotherapy, corresponding to similar studies in this manner.</offsets><sup><xref rid="R14" ref-type="bibr"><offsets xml_i="9107" xml_f="9109" txt_i="4431" txt_f="4433">14</offsets></xref><offsets xml_i="9116" xml_f="9117" txt_i="4433" txt_f="4434">,</offsets><xref rid="R17" ref-type="bibr"><offsets xml_i="9149" xml_f="9151" txt_i="4434" txt_f="4436">17</offsets></xref></sup><offsets xml_i="9164" xml_f="9872" txt_i="4436" txt_f="5144"> All the patients were over 18 years of age and had been treated with more than 4500cGy of radiation dose in 6.5 weeks more than 6 months previously. Patients with recurrent cancer, diabetes mellitus, asthma, consumption of antidepressant drugs and sensitivity to pilocarpine and bromhexine were excluded from the study. After taking an informed consent, the study was planned in 2 steps of A and B in order to reduce experimental errors. At step A, the patients were advised to use 5-mg pilocarpine tablets (Mahya Daroo Co.) 4 times daily for 2 weeks. After 2 weeks, the patients were asked to stop taking the drug for one week in order to obliterate the pharmacologic effects of the drug (wash-out period).</offsets><sup><xref rid="R18" ref-type="bibr"><offsets xml_i="9909" xml_f="9911" txt_i="5144" txt_f="5146">18</offsets></xref></sup><offsets xml_i="9924" xml_f="10410" txt_i="5146" txt_f="5632"> Then, they were asked to take 8-mg bromhexine tablets (Mucolin tablets, Tolidaroo Co.) 4 times daily for 2 weeks. The inverse process was conducted at step B (first bromhexine, then pilocarpine). The patients’ whole resting saliva was collected and measured precisely before and after every course of medication by two experts: one oral medicine specialist and one student of dentistry who was trained in this procedure. The resting saliva secretion was measured using spitting methods</offsets><sup><xref rid="R19" ref-type="bibr"><offsets xml_i="10447" xml_f="10449" txt_i="5632" txt_f="5634">19</offsets></xref></sup><offsets xml_i="10462" xml_f="10646" txt_i="5634" txt_f="5818"> and levels of lower than 0.01 mL reflected dysfunction of salivary glands. The patients were not informed about the prescribed drugs as dictated by the single-blind research design. 
</offsets></p><p><offsets xml_i="10653" xml_f="11088" txt_i="5819" txt_f="6254">
Then, the patients answered the self-administered questionnaire, during the first visit (zero day) and fourteen days after taking the medication; this was repeated for another drug in the same manner. The questionnaire was designed by a specialist of oral medicine in relation to dichotomous scale, including 15 questions about xerostomia and its oral complications such as swallowing, speech, tasting problems and burning sensation.
</offsets></p><p><offsets xml_i="11095" xml_f="11363" txt_i="6255" txt_f="6520">
Improvement of xerostomia and other oral complications was statistically analyzed by chi-squared and Fisher’s exact tests. Increase in saliva secretion, before and after medication, was analyzed by Student’s t-test. Statistical significance was defined at P&lt;0.05.
</offsets></p></sec><sec sec-type="results" id="s3"><title><offsets xml_i="11412" xml_f="11419" txt_i="6522" txt_f="6529">Results</offsets></title><p><offsets xml_i="11430" xml_f="11438" txt_i="6530" txt_f="6538">
Tables </offsets><xref rid="T1" ref-type="table"><offsets xml_i="11470" xml_f="11471" txt_i="6538" txt_f="6539">1</offsets></xref><offsets xml_i="11478" xml_f="11483" txt_i="6539" txt_f="6544"> and </offsets><xref rid="T2" ref-type="table"><offsets xml_i="11515" xml_f="11516" txt_i="6544" txt_f="6545">2</offsets></xref><offsets xml_i="11523" xml_f="11945" txt_i="6545" txt_f="6967"> show the rate of saliva secretion at step A (first pilocarpine, then bromhexine) and B (first bromhexine, then pilocarpine), respectively, in four separate evaluations: before and after first evaluation and before and after second evaluation. Comparisons between the rate of secretion showed no significant differences in bromhexine users (P=0.35) but there were significant differences in pilocarpine users (P=0.0001). 
</offsets></p><table-wrap id="T1" orientation="portrait" position="float"><label><offsets xml_i="12016" xml_f="12023" txt_i="6968" txt_f="6975">Table 1</offsets></label><caption><title><offsets xml_i="12047" xml_f="12172" txt_i="6975" txt_f="7100">Mean and SD of saliva secretion at step A (first pilocarpine, then bromhexine) before and after first and second evaluations </offsets></title></caption><table frame="hsides" rules="groups"><tbody><tr><td style=" border-width: 0px 0px 1px 0px; border-style: none none solid none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="12358" xml_f="12377" txt_i="7101" txt_f="7120">Time of evaluation
</offsets></td><td style=" border-width: 0px 0px 1px 0px; border-style: none none solid none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="12502" xml_f="12525" txt_i="7121" txt_f="7144">rate of secretion (mL)
</offsets></td></tr><tr><td style=" border-width: 0px 0px 0px 0px; border-style: none none none none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="12658" xml_f="12682" txt_i="7145" txt_f="7169">Before first evaluation
</offsets></td><td style=" border-width: 0px 0px 0px 0px; border-style: none none none none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="12806" xml_f="12816" txt_i="7170" txt_f="7180">0.08±0.02
</offsets></td></tr><tr><td style=" border-width: 0px 0px 0px 0px; border-style: none none none none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="12949" xml_f="12972" txt_i="7181" txt_f="7204">After first evaluation
</offsets></td><td style=" border-width: 0px 0px 0px 0px; border-style: none none none none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="13096" xml_f="13106" txt_i="7205" txt_f="7215">0.69±0.27
</offsets></td></tr><tr><td style=" border-width: 0px 0px 0px 0px; border-style: none none none none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="13239" xml_f="13264" txt_i="7216" txt_f="7241">Before second evaluation
</offsets></td><td style=" border-width: 0px 0px 0px 0px; border-style: none none none none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="13388" xml_f="13398" txt_i="7242" txt_f="7252">0.08±0.02
</offsets></td></tr><tr><td style=" border-width: 0px 0px 1px 0px; border-style: none none solid none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="13532" xml_f="13556" txt_i="7253" txt_f="7277">After second evaluation
</offsets></td><td style=" border-width: 0px 0px 1px 0px; border-style: none none solid none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="13681" xml_f="13691" txt_i="7278" txt_f="7288">0.11±0.06
</offsets></td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label><offsets xml_i="13797" xml_f="13804" txt_i="7289" txt_f="7296">Table 2</offsets></label><caption><title><offsets xml_i="13828" xml_f="13953" txt_i="7296" txt_f="7421">Mean and SD of saliva secretion at step B (first bromhexine, then pilocarpine) before and after first and second evaluations </offsets></title></caption><table frame="hsides" rules="groups"><tbody><tr><td style=" border-width: 1px 0px 1px 0px; border-style: solid none solid none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="14140" xml_f="14159" txt_i="7422" txt_f="7441">Time of evaluation
</offsets></td><td style=" border-width: 1px 0px 1px 0px; border-style: solid none solid none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="14285" xml_f="14308" txt_i="7442" txt_f="7465">rate of secretion (mL)
</offsets></td></tr><tr><td style=" border-width: 0px 0px 0px 0px; border-style: none none none none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="14441" xml_f="14466" txt_i="7466" txt_f="7491">Before first evaluation 
</offsets></td><td style=" border-width: 0px 0px 0px 0px; border-style: none none none none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="14590" xml_f="14600" txt_i="7492" txt_f="7502">0.08±0.02
</offsets></td></tr><tr><td style=" border-width: 0px 0px 0px 0px; border-style: none none none none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="14733" xml_f="14757" txt_i="7503" txt_f="7527">After first evaluation 
</offsets></td><td style=" border-width: 0px 0px 0px 0px; border-style: none none none none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="14881" xml_f="14891" txt_i="7528" txt_f="7538">0.09±0.01
</offsets></td></tr><tr><td style=" border-width: 0px 0px 0px 0px; border-style: none none none none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="15024" xml_f="15050" txt_i="7539" txt_f="7565">Before second evaluation 
</offsets></td><td style=" border-width: 0px 0px 0px 0px; border-style: none none none none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="15174" xml_f="15184" txt_i="7566" txt_f="7576">0.08±0.02
</offsets></td></tr><tr><td style=" border-width: 0px 0px 1px 0px; border-style: none none solid none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="15318" xml_f="15343" txt_i="7577" txt_f="7602">After second evaluation 
</offsets></td><td style=" border-width: 0px 0px 1px 0px; border-style: none none solid none;text-align:left;" rowspan="1" colspan="1"><offsets xml_i="15468" xml_f="15478" txt_i="7603" txt_f="7613">0.61±0.23
</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="15520" xml_f="15774" txt_i="7614" txt_f="7868">
Furthermore, 28% and 100% of bromhexine and pilocarpine users showed improvement of xerostomia after fourteen days, respectively. Statistical analysis showed significant differences in improvement of xerostomia for users of both medications (P=0.0001).
</offsets></p><p><offsets xml_i="15781" xml_f="16532" txt_i="7869" txt_f="8620">
All the (100%) pilocarpine users and 14.3% of bromhexine users demonstrated improvement of chewing difficulties; similarly, 87.5% of pilocarpine users and 25% of bromhexine users showed improvements in swallowing problems; 100% of pilocarpine users and 14.3% of bromhexine users, reported relief of speech problems and 90.9% of pilocarpine users and 20.8% bromhexine users showed improvements in tasting difficulties. Finally, 100% of pilocarpine users and 66.7% of bromhexine users demonstrated improvements in burning sensation. All the differences mentioned were statistically significant with P-values of 0.0001, 0.04, 0.005, 0.0001 and 0.004 for improvement in chewing, swallowing, speech, tasting problems and burning sensation, respectively. 
</offsets></p></sec><sec sec-type="discussion" id="s4"><title><offsets xml_i="16584" xml_f="16594" txt_i="8622" txt_f="8632">Discussion</offsets></title><p><offsets xml_i="16605" xml_f="17015" txt_i="8633" txt_f="9043">
Radiotherapy of head and neck may result in a decrease in salivary pH and its rate of secretion. Therefore, any discomfort of chewing, swallowing, speech and sleep may occur in the presence of xerostomia. In order to relieve these oral discomforts, salivary stimulating drugs, such as pilocarpine and bromhexine, have been used for some years and their efficacy has been verified in some experimental studies.</offsets><sup><xref rid="R10" ref-type="bibr"><offsets xml_i="17052" xml_f="17054" txt_i="9043" txt_f="9045">10</offsets></xref><offsets xml_i="17061" xml_f="17062" txt_i="9045" txt_f="9046">-</offsets><xref rid="R12" ref-type="bibr"><offsets xml_i="17094" xml_f="17096" txt_i="9046" txt_f="9048">12</offsets></xref></sup><offsets xml_i="17109" xml_f="17110" txt_i="9048" txt_f="9049">
</offsets></p><p><offsets xml_i="17117" xml_f="17218" txt_i="9050" txt_f="9151">
In the present study, improvement of xerostomia was shown using both medications. Chitapanarux et al</offsets><sup><xref rid="R17" ref-type="bibr"><offsets xml_i="17255" xml_f="17257" txt_i="9151" txt_f="9153">17</offsets></xref></sup><offsets xml_i="17270" xml_f="17285" txt_i="9153" txt_f="9168"> and Ram et al,</offsets><sup><xref rid="R20" ref-type="bibr"><offsets xml_i="17322" xml_f="17324" txt_i="9168" txt_f="9170">20</offsets></xref></sup><offsets xml_i="17337" xml_f="17473" txt_i="9170" txt_f="9306"> in line with this study, reported that pilocarpine has obvious palliative effects on xerostomia and sleep of patients. Previous studies</offsets><sup><xref rid="R21" ref-type="bibr"><offsets xml_i="17510" xml_f="17512" txt_i="9306" txt_f="9308">21</offsets></xref><offsets xml_i="17519" xml_f="17520" txt_i="9308" txt_f="9309">-</offsets><xref rid="R23" ref-type="bibr"><offsets xml_i="17552" xml_f="17554" txt_i="9309" txt_f="9311">23</offsets></xref></sup><offsets xml_i="17567" xml_f="17672" txt_i="9311" txt_f="9416"> have shown that pilocarpine has a great ability to prevent radiotherapy-induced xerostomia. Haddad et al</offsets><sup><xref rid="R24" ref-type="bibr"><offsets xml_i="17709" xml_f="17711" txt_i="9416" txt_f="9418">24</offsets></xref></sup><offsets xml_i="17724" xml_f="17780" txt_i="9418" txt_f="9474"> showed the preventive effect of both drugs and Wu et al</offsets><sup><xref rid="R25" ref-type="bibr"><offsets xml_i="17817" xml_f="17819" txt_i="9474" txt_f="9476">25</offsets></xref></sup><offsets xml_i="17832" xml_f="17996" txt_i="9476" txt_f="9640"> reported that pilocarpine can improve xerostomia induced by Sjögren syndrome. Although, some researchers have reported that pilocarpine increases saliva secretion,</offsets><sup><xref rid="R26" ref-type="bibr"><offsets xml_i="18033" xml_f="18035" txt_i="9640" txt_f="9642">26</offsets></xref><offsets xml_i="18042" xml_f="18043" txt_i="9642" txt_f="9643">,</offsets><xref rid="R27" ref-type="bibr"><offsets xml_i="18075" xml_f="18077" txt_i="9643" txt_f="9645">27</offsets></xref></sup><offsets xml_i="18090" xml_f="18272" txt_i="9645" txt_f="9827"> Warde et al, contrary to the results of the present stydy, reported no significant differences in recovery from xerostomia and quality of life between pilocarpine and placebo users.</offsets><sup><xref rid="R28" ref-type="bibr"><offsets xml_i="18309" xml_f="18311" txt_i="9827" txt_f="9829">28</offsets></xref></sup><offsets xml_i="18324" xml_f="18457" txt_i="9829" txt_f="9962"> It seems that use of VAS scale in their study and different frequencies of drug administration can explain this lack of difference.
</offsets></p><p><offsets xml_i="18464" xml_f="18561" txt_i="9963" txt_f="10060">
Notable effects of pilocarpine have been confirmed in improving radiotherapy-induced xerostomia,</offsets><sup><xref rid="R10" ref-type="bibr"><offsets xml_i="18598" xml_f="18600" txt_i="10060" txt_f="10062">10</offsets></xref><offsets xml_i="18607" xml_f="18608" txt_i="10062" txt_f="10063">-</offsets><xref rid="R12" ref-type="bibr"><offsets xml_i="18640" xml_f="18642" txt_i="10063" txt_f="10065">12</offsets></xref><offsets xml_i="18649" xml_f="18650" txt_i="10065" txt_f="10066">,</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="18682" xml_f="18684" txt_i="10066" txt_f="10068">24</offsets></xref></sup><offsets xml_i="18697" xml_f="18714" txt_i="10068" txt_f="10085"> Sjögren syndrome</offsets><sup><xref rid="R29" ref-type="bibr"><offsets xml_i="18751" xml_f="18753" txt_i="10085" txt_f="10087">29</offsets></xref></sup><offsets xml_i="18766" xml_f="18801" txt_i="10087" txt_f="10122"> and immune dysfunction conditions.</offsets><sup><xref rid="R30" ref-type="bibr"><offsets xml_i="18838" xml_f="18840" txt_i="10122" txt_f="10124">30</offsets></xref></sup><offsets xml_i="18853" xml_f="19020" txt_i="10124" txt_f="10291"> Given the efficacy of this medication in increasing saliva secretion, the practitioners have preferred to advise it rather than artificial saliva in these situations;</offsets><sup><xref rid="R31" ref-type="bibr"><offsets xml_i="19057" xml_f="19059" txt_i="10291" txt_f="10293">31</offsets></xref></sup><offsets xml_i="19072" xml_f="19306" txt_i="10293" txt_f="10527"> however, indication of pilocarpine prescription was limited in cases with complete suppression of salivary gland function. On the other hand, there are few scientific reports on bromhexine with definite results. However, Avisar et al</offsets><sup><xref rid="R32" ref-type="bibr"><offsets xml_i="19343" xml_f="19345" txt_i="10527" txt_f="10529">32</offsets></xref></sup><offsets xml_i="19358" xml_f="19381" txt_i="10529" txt_f="10552"> and Frost-larsen et al</offsets><sup><xref rid="R33" ref-type="bibr"><offsets xml_i="19418" xml_f="19420" txt_i="10552" txt_f="10554">33</offsets></xref></sup><offsets xml_i="19433" xml_f="19531" txt_i="10554" txt_f="10652"> showed improvement of xerostomia with administration of bromhexine in cases of Sjögren syndrome.
</offsets></p><p><offsets xml_i="19538" xml_f="19767" txt_i="10653" txt_f="10882">
The present study showed significant differences in all the signs and symptoms of radiotherapy-induced xerostomia using both medications, though pilocarpine showed a more effective role compared with bromhexine. Previous studies</offsets><sup><xref rid="R34" ref-type="bibr"><offsets xml_i="19804" xml_f="19806" txt_i="10882" txt_f="10884">34</offsets></xref><offsets xml_i="19813" xml_f="19814" txt_i="10884" txt_f="10885">-</offsets><xref rid="R36" ref-type="bibr"><offsets xml_i="19846" xml_f="19848" txt_i="10885" txt_f="10887">36</offsets></xref></sup><offsets xml_i="19861" xml_f="19972" txt_i="10887" txt_f="10998"> have shown significant increases in saliva secretion following pilocarpine administration. Frost-larsen et al,</offsets><sup><xref rid="R33" ref-type="bibr"><offsets xml_i="20009" xml_f="20011" txt_i="10998" txt_f="11000">33</offsets></xref></sup><offsets xml_i="20024" xml_f="20156" txt_i="11000" txt_f="11132"> in line with the present study, reported significant increases in saliva secretion after bromhexine administration but Misawa et al</offsets><sup><xref rid="R37" ref-type="bibr"><offsets xml_i="20193" xml_f="20195" txt_i="11132" txt_f="11134">37</offsets></xref></sup><offsets xml_i="20208" xml_f="20341" txt_i="11134" txt_f="11267"> could not find any significant differences. Different etiologies of xerostomia in these studies can probably explain the situation.
</offsets></p><p><offsets xml_i="20348" xml_f="20710" txt_i="11268" txt_f="11630">
The present single-blind study generally showed the superiority of Pilocarpine to Bromhexine in improving radiotherapy-induced xerostomia but further investigations are necessary to compare the long-term efficacy of these two drugs. In addition, application of quality of life questionnaire in 100-scale VAS might be a more precise evaluation of the situation.
</offsets></p></sec><sec sec-type="conclusion" id="s5"><title><offsets xml_i="20762" xml_f="20772" txt_i="11632" txt_f="11642">Conclusion</offsets></title><p><offsets xml_i="20783" xml_f="21021" txt_i="11643" txt_f="11881">
Pilocarpine is probably more effective in improving xerostomia and its associated problems compared with bromhexine, although the use of the latter was also shown to remove some consequences of radiotherapy in the head and neck region. 
</offsets></p></sec></body><back><ref-list><title>References</title><ref id="R01"><label>1</label><element-citation publication-type="journal"><name><surname>Mandel</surname><given-names>ID</given-names></name><article-title>The functions of saliva</article-title><source> J Dent Res </source><year>1987</year><volume>66</volume><fpage>623</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3497964</pub-id></element-citation></ref><ref id="R02"><label>2</label><element-citation publication-type="journal"><name><surname>Chambers</surname><given-names>MS</given-names></name><name><surname>Toth</surname><given-names>BB</given-names></name><name><surname>Martin</surname><given-names>JW</given-names></name><name><surname>Fleming</surname><given-names>TJ</given-names></name><name><surname>Lemon</surname><given-names>JC</given-names></name><article-title>Oral and dental management of the cancer patient: prevention and treatment of complications</article-title><source> Support Care Cancer </source><year>1995</year><volume>3</volume><fpage>168</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">7655777</pub-id></element-citation></ref><ref id="R03"><label>3</label><element-citation publication-type="journal"><name><surname>Ferguson</surname><given-names>MM</given-names></name><article-title>Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction</article-title><source> Oral Surg Oral Med Oral Pathol </source><year>1993</year><volume>75</volume><fpage>186</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">8093976</pub-id></element-citation></ref><ref id="R04"><label>4</label><mixed-citation publication-type="other">Burket LW, Greenberg M, Click M. Burket’s oral medicine 11<sup>th</sup> ed. BC Decker Inc; 2008.P. 214-5.</mixed-citation></ref><ref id="R05"><label>5</label><element-citation publication-type="journal"><name><surname>Greenberg</surname><given-names>MS</given-names></name><article-title>An update of the etiology and management of xerostomia</article-title><source> Oral Surg Oral Med Oral Pathol Oral Radiol Endod </source><year>2004</year><volume>97</volume><fpage>28</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">14716254</pub-id></element-citation></ref><ref id="R06"><label>6</label><element-citation publication-type="journal"><name><surname>Regelink</surname><given-names>G</given-names></name><name><surname>Vissink</surname><given-names>A</given-names></name><name><surname>Reintsema</surname><given-names>H</given-names></name><name><surname>Nauta</surname><given-names>JM</given-names></name><article-title>Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia</article-title><source> Quint Int </source><year>1998</year><volume> 29</volume><fpage>383</fpage><lpage>8</lpage></element-citation></ref><ref id="R07"><label>7</label><mixed-citation publication-type="other">Jay SC. Moss Radiation Oncology 7th Ed. The CV Mosby Co;1994:205.</mixed-citation></ref><ref id="R08"><label>8</label><element-citation publication-type="journal"><name><surname>Valdes Olmos</surname><given-names> RA</given-names></name><name><surname>Kevs</surname><given-names>RB</given-names></name><article-title>Scintigraphic assessment of salivary function and excretion response in radiation induced injury of the major salivary glands</article-title><source> Cancer </source><year>1994</year><volume>73</volume><fpage>2886</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">8199984</pub-id></element-citation></ref><ref id="R09"><label>9</label><element-citation publication-type="journal"><name><surname>Brown</surname><given-names>LR</given-names></name><name><surname>Dreizen</surname><given-names>S</given-names></name><name><surname>Handler</surname><given-names>S</given-names></name><name><surname>Johnston</surname><given-names>DA</given-names></name><article-title>Effect of radiation-induced xerostomia on human oral microflora</article-title><source> J Dent Res </source><year>1975</year><volume>54</volume><fpage>740</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">1099136</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><name><surname>LeVeque</surname><given-names>FG</given-names></name><name><surname>Montgomery</surname><given-names>M</given-names></name><name><surname>Potter</surname><given-names>D</given-names></name><name><surname>Zimmer</surname><given-names>MB</given-names></name><name><surname>Rieke</surname><given-names>JW</given-names></name><name><surname>Steiger</surname><given-names>BW</given-names></name><etal></etal><article-title>A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients</article-title><source> J Clin Oncol </source><year>1993</year><volume>11</volume><fpage>1124</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">8501499</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><name><surname>Horiot</surname><given-names>JC</given-names></name><name><surname>Lipinski</surname><given-names>F</given-names></name><name><surname>Schraub</surname><given-names>S</given-names></name><name><surname>Maulard-Durdux</surname><given-names>C</given-names></name><name><surname>Bensadoun</surname><given-names>RJ</given-names></name><name><surname>Ardiet</surname><given-names>JM</given-names></name><etal></etal><article-title>Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study</article-title><source> Radiother Oncol </source><year>2000</year><volume>55</volume><fpage>233</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11041775</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><name><surname>Johnson</surname><given-names>JT</given-names></name><name><surname>Ferretti</surname><given-names>GA</given-names></name><name><surname>Nethery</surname><given-names>WJ</given-names></name><name><surname>Valdez</surname><given-names>IH</given-names></name><name><surname>Fox</surname><given-names>PC</given-names></name><name><surname>Ng</surname><given-names>D</given-names></name><etal></etal><article-title>Oral pilocarpine for postirradiation xerostomia in patients with head and neck cancer</article-title><source> N Engl J Med </source><year>1993</year><volume>329</volume><fpage>390</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8326972</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><name><surname>Davies</surname><given-names>AN</given-names></name><article-title>A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer</article-title><source> Palliative Medicine </source><year>2000</year><volume>14</volume><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">10858827</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><name><surname>Haddad</surname><given-names>P</given-names></name><name><surname>Karimi</surname><given-names>M</given-names></name><article-title>A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia</article-title><source> Radiotherapy and Oncology </source><year>2002</year><volume>64</volume><fpage>29</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">12208571</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><name><surname>Sweeney</surname><given-names>MP</given-names></name><name><surname>Bagg</surname><given-names>J</given-names></name><name><surname>Baxter</surname><given-names>WP</given-names></name><name><surname>Aitchison</surname><given-names>Tc</given-names></name><article-title>Clinical trial of a mucin containing oral spray for treatment of xerostomia in hospice patients</article-title><source> Palliative medicine </source><year>1997</year><volume> 11</volume><fpage>225</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">9205656</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><name><surname>Fox</surname><given-names>PC</given-names></name><article-title>Salivary enhancement therapies</article-title><source> Caries Res </source><year>2004</year><volume>38</volume><fpage>241</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15153695</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><name><surname>Chitapanarux</surname><given-names>I</given-names></name><name><surname>Kamnerdsupaphon</surname><given-names>P</given-names></name><name><surname>Tharavichitkul</surname><given-names>E</given-names></name><name><surname>Sumitsawan</surname><given-names>Y</given-names></name><name><surname>Sittitrai</surname><given-names>P</given-names></name><name><surname>Pattarasakulchai</surname><given-names>T</given-names></name><etal></etal><article-title>Effect of Oral Pilocarpine on Post-Irradiation Xerostomia in Head and Neck Cancer Patients. A Single-Center, Single-Blind Clinical Trial</article-title><source>J Med Assoc Thai </source><year>2008</year><volume>91</volume><fpage>1410</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18843872</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><name><surname>Matzneller</surname><given-names>P</given-names></name><name><surname>Burian</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>W</given-names></name><name><surname>Annoni</surname><given-names>O</given-names></name><name><surname>Lauro</surname><given-names>V</given-names></name><name><surname>Tacchi</surname><given-names>R </given-names></name><etal></etal><article-title>A Randomised, Two-Period, Cross-Over, Open-Label Study to Evaluate the Pharmacokinetic Profiles of Single Doses of Two Different urbiprofen 8.75-mg Loz-enges in Healthy Volunteers</article-title><source>Pharmacology </source><year>2012</year><volume>89</volume><fpage>188</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">22433300</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><name><surname>Kakoei</surname><given-names>S</given-names></name><name><surname>Haghdoost</surname><given-names>AA</given-names></name><name><surname>Rad</surname><given-names>M</given-names></name><name><surname>Mohammadalizadeh</surname><given-names>S</given-names></name><name><surname>Pourdamghan</surname><given-names>N</given-names></name><name><surname>Nakhaei</surname><given-names>M</given-names></name><etal></etal><article-title>Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients</article-title><source> Arch Iran Med </source><year>2012</year><volume>15</volume><fpage>214</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">22424038</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><name><surname>Ram</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Navazesh</surname><given-names>M</given-names></name><article-title>Management of xerostomia and salivary gland hypofunction</article-title><source> J Calif Dent Assoc </source><year>2011</year><volume>39</volume><fpage>656</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22034800</pub-id></element-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal">Fardesfahani A, Moddaress M. Quantative evaluation of salivary gland function with Radioisotope Tc99m scan for prevention of radiotherapy-induced xerostomia. Journal of Iran Nuclear medicine 2006;3: 11-20 [Persian].</mixed-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><name><surname>Reiger</surname><given-names>JM</given-names></name><name><surname>Gha</surname><given-names>N</given-names></name><name><surname>Lam Tang</surname><given-names>JA</given-names></name><article-title>Functional outcomes related to the prevention of radiation-induced xerostomia: Oral Pilocarpine versus submandibular salivary gland transfer</article-title><source> Head Neck </source><year>2012</year><volume> 34</volume><fpage>168</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">21416547</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><name><surname>Berk</surname><given-names>L</given-names></name><article-title>Systemic pilocarpine for treatment of xerostomia</article-title><source> Expert Opin Drug Metab Toxicol </source><year>2008</year><volume> 4</volume><fpage>1333</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">18798702</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><name><surname>Ho</surname><given-names>C</given-names></name><name><surname>Murray</surname><given-names>N</given-names></name><name><surname>Laskin</surname><given-names>J</given-names></name><article-title>Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America</article-title><source> Lung Cancer </source><year>2005</year><volume>49</volume><fpage>225</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">15925429</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><name><surname>Wu</surname><given-names>CH</given-names></name><name><surname>Hsieh</surname><given-names>SC</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Li</surname><given-names>KJ</given-names></name><name><surname>Lu</surname><given-names>MC</given-names></name><name><surname>Yu</surname><given-names>CL</given-names></name><article-title>Pilocarpine Hydrochloride for the Treatment of Xerostomia in Patients with Sjogren's Syndrome in Taiwan - A Double-blind, Placebo-controlled Trial</article-title><source> J Formos Med Assoc </source><year>2006</year><volume>105</volume><fpage>796</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">17000452</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><name><surname>Papas</surname><given-names>A</given-names></name><name><surname>Charney</surname><given-names>M</given-names></name><name><surname>Goden</surname><given-names>H</given-names></name><article-title>The effectiveness of oral pilocarpine-HCL tablets for the treatment of dry mouth symptoms associated with Sjِgren’s syndrome- a dosetitration study</article-title><source> Arthritis Rheum </source><year>1997</year><volume>40</volume><fpage>202</fpage></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><name><surname>Vivino</surname><given-names>FB</given-names></name><name><surname>Al-Hashimi</surname><given-names>I</given-names></name><name><surname>Khan</surname><given-names>Z</given-names></name><article-title>Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjِgren’s syndrome: a randomized, placebocontrolled, fixed-dose, multicenter trial. P92-01 Study Group</article-title><source>Arch Intern Med </source><year>1999</year><volume>159</volume><fpage>174</fpage><lpage>81</lpage></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><name><surname>Warde</surname><given-names>P</given-names></name><name><surname>O'Sullivan</surname><given-names>B</given-names></name><name><surname>Aslanidis</surname><given-names>J</given-names></name><name><surname>Kroll</surname><given-names>B</given-names></name><name><surname>Lockwood</surname><given-names>G</given-names></name><name><surname>Waldron</surname><given-names>J</given-names></name><article-title>A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer</article-title><source> Int J Radiat Oncol Biol Phys </source><year>2002</year><volume>54</volume><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">12182969</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><name><surname>Vivino</surname><given-names>FB</given-names></name><article-title>The treatment of Sjogren syndrome patients with Pilocarpine-tablets</article-title><source> Scand J Ruematol Suppl </source><year>2001</year><volume>115</volume><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><name><surname>Fox</surname><given-names>PC</given-names></name><name><surname>Vander Ven</surname><given-names> PF</given-names></name><name><surname>Baum</surname><given-names>BJ</given-names></name><article-title>Pilocarpine for treatment of xerostomia associated with salivary gland dysfunction</article-title><source> Oral Surg Oral Med Oral Pathol </source><year>1986</year><volume>619</volume><fpage>243</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">3517744</pub-id></element-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal">Soto-Rojas AE, Kraus A: The oral side of Sjogren syndrome; Diagnosis and treatment; A review. Arch Med Res 2002;33:95-106.</mixed-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><name><surname>Avisar</surname><given-names>R</given-names></name><name><surname>Savir</surname><given-names>H</given-names></name><name><surname>Machtey</surname><given-names>I</given-names></name><name><surname>Ovaknin</surname><given-names>L</given-names></name><name><surname>Shaked</surname><given-names>P</given-names></name><name><surname>Menache</surname><given-names>R </given-names></name><etal></etal><article-title>Clinical trial of bromhexine in Sjogren's syndrome</article-title><source> Ann Ophthalmol </source><year>1981</year><volume>13</volume><fpage>971</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">7027873</pub-id></element-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal">Frost-Larsen K, Isager H, Manthorpe R. Sjogren's syndrome treated with bromhexine: a randomised clinical study. Br Med J 1978;1579-81.</mixed-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><name><surname>Scarantino</surname><given-names>C</given-names></name><name><surname>LeVeque</surname><given-names>F</given-names></name><name><surname>Swann</surname><given-names>RS</given-names></name><name><surname>White</surname><given-names>R</given-names></name><name><surname>Schulsinger</surname><given-names>A</given-names></name><name><surname>Hodson</surname><given-names>DI </given-names></name><etal></etal><article-title>Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients</article-title><source> J Support Oncol </source><year>2006</year><volume>4</volume><fpage>252</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16724649</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><name><surname>Bernardi</surname><given-names>R</given-names></name><name><surname>Pein</surname><given-names>C</given-names></name><name><surname>Becker</surname><given-names>FL</given-names></name><name><surname>Ramos</surname><given-names>GZ</given-names></name><name><surname>Gheno</surname><given-names>GZ</given-names></name><name><surname>Lopez</surname><given-names>LR </given-names></name><etal></etal><article-title>Effect of Pilocarpine mouthwash on salivary flow</article-title><source> Brazilian Journal of Medical and Biological Research </source><year>2002</year><volume>35</volume><fpage>105</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">11743622</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><name><surname>Taweechaisupapong</surname><given-names>S</given-names></name><name><surname>Pesee</surname><given-names>M</given-names></name><name><surname>Aromdee</surname><given-names>C</given-names></name><name><surname>Laopaiboon</surname><given-names>M</given-names></name><name><surname>Khunkitti</surname><given-names>W</given-names></name><article-title>Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer</article-title><source> Aust Dent J </source><year>2006</year><volume>51</volume><fpage>333</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17256309</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><name><surname>Misawa</surname><given-names>M</given-names></name><name><surname>Ohmori</surname><given-names>SH</given-names></name><name><surname>Yanaura</surname><given-names>S</given-names></name><article-title>Effects of Bromhexidine on the secretions of saliva and tears</article-title><source> The Japanese Journal of Pharamcology </source><year>1985</year><volume>39</volume><fpage>241</fpage><lpage>50</lpage></element-citation></ref></ref-list></back></article>